» Articles » PMID: 31767751

High-throughput Assessment of Hemoglobin Polymer in Single Red Blood Cells from Sickle Cell Patients Under Controlled Oxygen Tension

Overview
Specialty Science
Date 2019 Nov 27
PMID 31767751
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD) is caused by a variant hemoglobin molecule that polymerizes inside red blood cells (RBCs) in reduced oxygen tension. Treatment development has been slow for this typically severe disease, but there is current optimism for curative gene transfer strategies to induce expression of fetal hemoglobin or other nonsickling hemoglobin isoforms. All SCD morbidity and mortality arise directly or indirectly from polymer formation in individual RBCs. Identifying patients at highest risk of complications and treatment candidates with the greatest curative potential therefore requires determining the amount of polymer in individual RBCs under controlled oxygen. Here, we report a semiquantitative measurement of hemoglobin polymer in single RBCs as a function of oxygen. The method takes advantage of the reduced oxygen affinity of hemoglobin polymer to infer polymer content for thousands of RBCs from their overall oxygen saturation. The method enables approaches for SCD treatment development and precision medicine.

Citing Articles

High-throughput quantification of red blood cell deformability and oxygen saturation to probe mechanisms of sickle cell disease.

Williams D, Wood D Proc Natl Acad Sci U S A. 2023; 120(48):e2313755120.

PMID: 37983504 PMC: 10691249. DOI: 10.1073/pnas.2313755120.


Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling.

De Souza D, Hebert N, Esrick E, Ciuculescu M, Archer N, Armant M Nat Commun. 2023; 14(1):5850.

PMID: 37730674 PMC: 10511721. DOI: 10.1038/s41467-023-40923-5.


Biosynthesis of High-Active Hemoproteins by the Efficient Heme-Supply Pichia Pastoris Chassis.

Yu F, Zhao X, Zhou J, Lu W, Li J, Chen J Adv Sci (Weinh). 2023; 10(30):e2302826.

PMID: 37649147 PMC: 10602571. DOI: 10.1002/advs.202302826.


Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.

Metaferia B, Cellmer T, Dunkelberger E, Li Q, Henry E, Hofrichter J Proc Natl Acad Sci U S A. 2022; 119(40):e2210779119.

PMID: 36161945 PMC: 9546543. DOI: 10.1073/pnas.2210779119.


Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.

Vunnam N, Hansen S, Williams D, Been M, Lo C, Pandey A Biomacromolecules. 2022; 23(9):3822-3830.

PMID: 35944154 PMC: 9472799. DOI: 10.1021/acs.biomac.2c00671.


References
1.
Ferrone F . The delay time in sickle cell disease after 40 years: A paradigm assessed. Am J Hematol. 2015; 90(5):438-45. DOI: 10.1002/ajh.23958. View

2.
Steinberg M, Chui D, Dover G, Sebastiani P, Alsultan A . Fetal hemoglobin in sickle cell anemia: a glass half full?. Blood. 2013; 123(4):481-5. DOI: 10.1182/blood-2013-09-528067. View

3.
Eaton W, Hofrichter J . Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990; 40:63-279. DOI: 10.1016/s0065-3233(08)60287-9. View

4.
Schonbrun E, Di Caprio G, Schaak D . Dye exclusion microfluidic microscopy. Opt Express. 2013; 21(7):8793-8. DOI: 10.1364/OE.21.008793. View

5.
Ivanova M, Jasuja R, Kwong S, Briehl R, Ferrone F . Nonideality and the nucleation of sickle hemoglobin. Biophys J. 2000; 79(2):1016-22. PMC: 1300997. DOI: 10.1016/S0006-3495(00)76355-7. View